[
  {
    "ts": null,
    "headline": "AbbVie’s Phase III trial of atogepant for migraine meets primary goal",
    "summary": "A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.",
    "url": "https://finnhub.io/api/news?id=5d1476f8a2e82dad2e85d248507638d6046c4fe8f1ec931614bfc6819b47605e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750342005,
      "headline": "AbbVie’s Phase III trial of atogepant for migraine meets primary goal",
      "id": 135396817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.",
      "url": "https://finnhub.io/api/news?id=5d1476f8a2e82dad2e85d248507638d6046c4fe8f1ec931614bfc6819b47605e"
    }
  }
]